Metaplastic breast cancer: A review

Horatio R Thomas; Bonnie Hu; Baris Boyraz; Andrew Johnson; Veerle I Bossuyt; Laura Spring; Rachel B Jimenez

doi:10.1016/j.critrevonc.2023.103924

Metaplastic breast cancer: A review

Crit Rev Oncol Hematol. 2023 Feb:182:103924. doi: 10.1016/j.critrevonc.2023.103924. Epub 2023 Jan 22.

Authors

Horatio R Thomas¹, Bonnie Hu², Baris Boyraz³, Andrew Johnson², Veerle I Bossuyt³, Laura Spring⁴, Rachel B Jimenez²

Affiliations

¹ Department of Radiation Oncology, University of California, San Francisco, United States. Electronic address: horatio.thomas@ucsf.edu.
² Department of Radiation Oncology, Massachusetts General Hospital, United States.
³ Department of Pathology, Massachusetts General Hospital, United States.
⁴ Department of Medicine, Division of Medical Oncology, Massachusetts General Hospital, United States.

PMID: 36696934
DOI: 10.1016/j.critrevonc.2023.103924

Abstract

Metaplastic breast cancer (MpBC) is an uncommon aggressive malignancy that is associated with a poor prognosis. Due to its rarity, the relationships between the clinical and pathological features of MpBC, treatment approach, and clinical outcomes remain underexplored. In the following review article, we synthesize the existing data on the clinical, pathological and genomic features, management, and outcomes of MpBC. We also identify potential targets for future clinical trials.

Keywords: Clinical management; Clinical outcomes; Epithelial-to-mesenchymal transition; Immunotherapy; Metaplastic breast cancer; Pathology; Targeted therapy.

Publication types

Review

MeSH terms

Breast Neoplasms* / diagnosis
Breast Neoplasms* / genetics
Breast Neoplasms* / therapy
Female
Genomics
Humans